GSK, CureVac team up to develop and manufacture vaccine against COVID-19 mutants

Image Credit: CureVac

UK-based GlaxoSmithKline announced today that it has partnered with German pharmaceutical company CureVac to jointly develop next-generation mRNA vaccines for emerging COVID-19 variants.

The €150m collaboration will build on the two companies’ existing relationship.

Under the co-development agreement, GSK and CureVac will combine their scientific expertise to research, develop, and manufacture several vaccine candidates hoping to offer protection against multiple emerging SARS-CoV2 variants.

Commenting on the agreement, GSK Chief Executive Officer Emma Walmsley said: “We believe that next-generation vaccines will be crucial in the continued fight against COVID-19.”

GSK is also set to manufacture over 100 million doses of CVnCoV, CureVac’s first generation COVID-19 jab, using its manufacturing network in Belgium.

New vaccine candidates will build upon the CVnCoV, which is currently in Phase 2b/3 clinical trial. The collaboration will also improve upon CureVac’s manufacturability and stability at standard vaccine storage conditions.

Development of the new jabs will begin immediately, with roll-out expected in 2022, subject to regulatory approval.

“We are very pleased to build on our existing relationship with GSK with a new agreement to jointly develop next-generation mRNA-based vaccines, in addition to our current candidate CVnCoV,” said Franz-Werner Haas, Chief Executive Officer of CureVac.

“With the help of GSK’s proven vaccine expertise, we are equipping ourselves to tackle future health challenges with novel vaccines.”

Notify of
Inline Feedbacks
View all comments